Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL
Articolo
Data di Pubblicazione:
2017
Abstract:
Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Antiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability
Elenco autori:
Madeddu G, Rusconi S; Icona, Foundation Study G. r. o. u. p.; QUIROS ROLDAN, Maria Eugenia
Link alla scheda completa:
Pubblicato in: